Protocol A011-13 (HYPERION): A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Sotatercept When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy in Newly Diagnosed Intermediate- and High-risk PAH Patients
Primary Objective
To evaluate the effects of sotatercept treatment versus placebo on TTCW in participants who are newly diagnosed with PAH and are at intermediate or high risk of PAH progression.
Details
Age
Adult
Type of Study
Treatment
Scope
National
Locations
University of Colorado Hospital
Principal Investigator
David Badesch, MD
Study ID
Protocol Number: 21-3600
More information available at ClinicalTrials.gov: NCT04811092
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers